Relacorilant (CORT125134)

Key Takeaways

• FDA approves relacorilant (Lifyorli) with nab‑paclitaxel for platinum‑resistant ovarian cancer
• Selective GR antagonist blocks cortisol signaling without affecting other steroid receptors
• Approval shifts relacorilant from endocrine focus to Corcept’s key oncology asset
• Combination therapy targets a high‑unmet‑need patient population with limited options
• Success may spur further trials of GR antagonists in other solid tumors

Pulse Analysis

Cortisol’s interaction with the glucocorticoid receptor (GR) has long been implicated in tumor growth, immune evasion, and chemotherapy resistance. Traditional cortisol‑pathway drugs affect multiple steroid receptors, leading to off‑target side effects that limit their clinical utility. Relacorilant’s design as a highly selective GR antagonist allows it to blunt cortisol‑driven signaling while preserving the activity of androgen, estrogen, and mineralocorticoid receptors, offering a cleaner pharmacologic profile for both endocrine and oncologic applications.

The FDA’s decision follows a pivotal Phase III trial that demonstrated a statistically significant improvement in progression‑free survival when relacorilant was added to nab‑paclitaxel versus chemotherapy alone in platinum‑resistant ovarian cancer patients. The combination was well tolerated, with adverse events comparable to standard chemotherapy, and provided a meaningful response rate in a cohort that historically has few effective options. By addressing a molecular driver rather than relying solely on cytotoxic mechanisms, the regimen exemplifies the shift toward precision oncology in hard‑to‑treat gynecologic malignancies.

From a market perspective, the approval positions Corcept to capture a slice of the $5 billion ovarian cancer treatment market, especially as clinicians seek alternatives to repeat platinum therapy. The success also validates the broader strategy of repurposing endocrine‑focused molecules for oncology, likely spurring investment in additional GR‑targeted trials across solid tumors such as lung and pancreatic cancer. Investors will watch Corcept’s upcoming earnings for early revenue signals, while competitors may accelerate their own glucocorticoid‑axis programs to keep pace with this emerging therapeutic class.